Stephen Tatter to Antineoplastic Agents, Alkylating
This is a "connection" page, showing publications Stephen Tatter has written about Antineoplastic Agents, Alkylating.
Connection Strength
0.828
-
Mu F, Lucas JT, Watts JM, Johnson AJ, Daniel Bourland J, Laxton AW, Chan MD, Tatter SB. Tumor resection with carmustine wafer placement as salvage therapy after local failure of radiosurgery for brain metastasis. J Clin Neurosci. 2015 Mar; 22(3):561-5.
Score: 0.488
-
McTyre E, Lucas JT, Helis C, Farris M, Soike M, Mott R, Laxton AW, Tatter SB, Lesser GJ, Strowd RE, Lo HW, Debinski W, Chan MD. Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide. Am J Clin Oncol. 2018 08; 41(8):813-819.
Score: 0.156
-
Renfrow JJ, Detroye A, Chan M, Tatter S, Ellis T, McMullen K, Johnson A, Mott R, Lesser GJ. Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report. J Neurooncol. 2012 May; 107(3):659-63.
Score: 0.099
-
Olivi A, Grossman SA, Tatter S, Barker F, Judy K, Olsen J, Bruce J, Hilt D, Fisher J, Piantadosi S. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. J Clin Oncol. 2003 May 01; 21(9):1845-9.
Score: 0.054
-
Paulsson AK, McMullen KP, Peiffer AM, Hinson WH, Kearns WT, Johnson AJ, Lesser GJ, Ellis TL, Tatter SB, Debinski W, Shaw EG, Chan MD. Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Am J Clin Oncol. 2014 Apr; 37(2):177-81.
Score: 0.029